Q-Line BiotechNSE:QLINE -5.15%12 ROE % is 15.99% as of Mar. 2025, which is 33% below its 10-year median of 23.83. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 86.95% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Q-Line Biotech's annualized net income for the quarter that ended in Mar. 2025 was ₹281 Mil. Q-Line Biotech's average Total Stockholders Equity over the quarter that ended in Mar. 2025 was ₹1,759 Mil. Therefore, Q-Line Biotech's annualized ROE % for the quarter that ended in Mar. 2025 was 15.99%.
The historical rank and industry rank for Q-Line Biotech's ROE % or its related term are showing as below:
NSE:QLINE'
s ROE % Range Over the Past 10 Years
Min: 15.99 Med: 23.83 Max: 25.2
Current: 15.99
During the past 3 years, Q-Line Biotech's highest ROE % was 25.20%. The lowest was 15.99%. And the median was 23.83%.
NSE:QLINE's ROE % is ranked better than 86.95% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs NSE:QLINE: 15.99
Q-Line Biotech (NSE:QLINE) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is one times the annual (Mar. 2025) net income data. The Revenue data used here is one times the annual (Mar. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Q-Line Biotech ROE % Related Terms
Q-Line Biotech ROE % Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech ROE % Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
ROE %
25.20
23.83
15.99
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
ROE %
25.20
23.83
15.99
NSE:QLINE vs ABT, SYK, MDT: ROE % Comparison
For the Medical Devices subindustry, Q-Line Biotech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's ROE % distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Mar. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Q-Line Biotech (NSE:QLINE) has a ROE % of 15.99% as of Mar. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Q-Line Biotech and its competitors. This is 33% below median its historical median of 23.83. Over the past decade, Q-Line Biotech's ROE % has ranged from 15.99 to 25.20. According to the industry distribution chart, Q-Line Biotech ranks #104 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 13%.
Is Q-Line Biotech's ROE % too high?
Q-Line Biotech's current ROE % of 15.99% is 33% below median its 10-year median of 23.83. Over the past 10 years, this metric has ranged from a low of 15.99 to a high of 25.20. The Medical Devices & Instruments industry median ROE % is 2.40. Q-Line Biotech's value of 15.99% is 566.3% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #104 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #104 out of 797 companies for ROE %. This places Q-Line Biotech in the top 13% of its industry — outperforming the majority of peers. The industry median ROE % is 2.40. Q-Line Biotech's value of 15.99% is 566.3% above this benchmark. Historically, Q-Line Biotech's own ROE % has ranged from 15.99 to 25.20 over the past decade. While the company's 10-year median is 23.83 vs. the industry median of 2.40, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current ROE % of 15.99% is 566.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current ROE % is 15.99%, which is 33% below median its own 10-year median of 23.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current ROE % of 15.99%. The current ROE % is 15.99%, which is 33% below median its 10-year median of 23.83 and 566.3% above the Medical Devices & Instruments industry median of 2.40. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current ROE % is 15.99% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 